Capricor Therapeutics Stock Slides As Q4 Earnings Miss Estimates

Core Viewpoint - Capricor Therapeutics is experiencing bearish pressure on its stock due to disappointing financial results, despite positive developments in its clinical trials and analyst support. Financial Performance - Capricor reported a quarterly loss of 62 cents per share, missing the consensus estimate of a 54-cent loss and worsening from a 16-cent loss in the prior-year period [2] - Quarterly revenue fell to zero from approximately $11.1 million a year earlier, while total operating expenses increased to roughly $29.2 million from $18.8 million [2] - The fourth-quarter net loss widened to about $30.2 million from $7.1 million [2] Clinical Developments - Capricor announced that its Phase 3 HOPE-3 trial met its primary endpoint, which is a positive indicator for the company's future prospects [3] - The biologics license application for deramiocel is currently under FDA review, with a PDUFA target action date set for August 22 [3] Cash Position - As of the end of 2025, Capricor had approximately $318.1 million in cash, cash equivalents, and marketable securities, which is expected to fund operations through 2027 [3] Analyst Ratings - HC Wainwright reiterated a Buy rating with a price target of $60, while Piper Sandler raised its price target to $58 from $45, maintaining an Overweight rating [4] Stock Performance - Capricor shares have shown strong bullish momentum, rising from a low of about $4.60 in late 2025 to a recent high near $33.57 [5] - The stock is currently trading well above its 20-, 50-, and 200-day moving averages, indicating strong bullish momentum [5] Recent Price Action - As of the latest publication, Capricor Therapeutics shares were down 5.69% at $31.52 [6]